Jun-ren Zhu

发表

Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy

P. Gao, Shu-yang Zhang, Jun-ren Zhu, 2014, Archives of Pharmacal Research.

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

J. Laragh, A. Zanchetti, S. Kjeldsen, 2006, Hypertension.

Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.

I. Marschner, Y. Jang, J. Ge, 2010, Journal of cardiology.

Tolerability of Ramipril 10 mg/day in High-Risk Cardiovascular Chinese Patients

Kan Chen, Jun-ren Zhu, N. Wu, 2002 .

Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.

Xuening Li, Jun-ren Zhu, Wei-li Chen, 2010, Clinical therapeutics.

Efficacy and Tolerability of a Single-Pill Combination of Amlodipine/Valsartan in Asian Hypertensive Patients Not Adequately Controlled with Valsartan Monotherapy

Jun Huang, Jun-ren Zhu, N. Sun, 2011, Clinical and experimental hypertension.

Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.

Y. Jang, J. Ge, Young-Jo Kim, 2014, Journal of cardiology.

A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)

K. Sim, B. Tomlinson, Y. Ro, 2007, Current medical research and opinion.

Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial

J. Ge, B. Hong, P. Pinton, 2010, Current medical research and opinion.

Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies

D. Bilheimer, T. Loeys, N. Chung, 2004, Current medical research and opinion.

[Differences in goal attainment in clinical management of dyslipidemia in China evaluated by different guidelines].

Yang-feng Wu, Lian-cheng Zhao, Zuo Chen, 2009, Zhonghua xin xue guan bing za zhi.

A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.

P. Ye, Jun-ren Zhu, 2003, Chinese medical journal.

Long-Term Efficacy of Olmesartan Medoxomil in Chinese Hypertensive Patients as Assessed by Clinic, Ambulatory and Home Blood Pressure Measurements

Ji-Guang Wang, Jun-ren Zhu, N. Sun, 2012, Clinical Drug Investigation.

Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension

D. Keefe, Jun-ren Zhu, N. Sun, 2012, Hypertension Research.

Tolerability of beta‐blockers in elderly patients with chronic heart failure: The COLA II study

H. Krum, F. Fruhwald, J. Kragten, 2006, European journal of heart failure.

Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.

Ji-Guang Wang, Y. Jiao, Jun-ren Zhu, 2012, European review for medical and pharmacological sciences.

Residual macrovascular risk in 2013: what have we learned?

A. Gotto, D. Rader, M. Krempf, 2014, Cardiovascular Diabetology.

2016 Chinese guidelines for the management of dyslipidemia in adults

Jian‐Jun Li, R. Gao, Shuiping Zhao, 2018, Journal of geriatric cardiology : JGC.

Dronedarone in high-risk permanent atrial fibrillation.

D. Atar, S. Yusuf, Jun Zhu, 2011, The New England journal of medicine.

A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study

J. Le Heuzey, M. Santini, J. Davy, 2010, Journal of cardiovascular electrophysiology.

Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

P. Pais, Á. Avezum, A. Parkhomenko, 2016, Journal of the American Heart Association.

Darapladib for preventing ischemic events in stable coronary heart disease.

P. Pais, Á. Avezum, A. Parkhomenko, 2014, The New England journal of medicine.

Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring

Ji-Guang Wang, Hong Jiang, Jun-ren Zhu, 2012, Blood pressure monitoring.

Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy

Shu-yang Zhang, Jun-ren Zhu, P. Gao, 2014, Archives of pharmacal research.

Shanghai trial of nifedipine in the elderly

P. Hamet, P. Ghadirian, J. LeLorier, 1996 .

Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension

Yanxing Zhao, Jun-ren Zhu, N. Sun, 2008 .

Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy

Dingliang Zhu, Jun-ren Zhu, Y. Ke, 2010, Current medical research and opinion.

[Cut offs and risk stratification of dyslipidemia in Chinese adults].

Y. Li, Jing Liu, Bei-fan Zhou, 2007, Zhonghua xin xue guan bing za zhi.

2016 Chinese guidelines for the management of dyslipidemia in adults

Jian‐Jun Li, R. Gao, Shuiping Zhao, 2018, Journal of geriatric cardiology : JGC.

Shanghai trial of nifedipine in the elderly (STONE).

P. Hamet, J. Zhu, P. Ghadirian, 1996, Journal of hypertension.

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.

B. Jelaković, A. Manolis, K. Woo, 2000, Clinical therapeutics.

[Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy].

Jun Huang, Jun-ren Zhu, Y. Ke, 2009, Zhonghua xin xue guan bing za zhi.

[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients].

Jun-ren Zhu, N. Sun, Hong-yi Wang, 2007, Zhonghua xin xue guan bing za zhi.